---
title: "MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285419979.md"
description: "Wedbush analyst Yun Zhong has reiterated a Buy rating for MannKind (MNKD) stock, maintaining an $8 price target. This decision is based on MannKind's expanding role in United Therapeutics' inhaled portfolio and the potential of the ralinepag DPI program. United Therapeutics' exercise of an exclusive option for a second DPI product highlights confidence in MannKind's technology. The report also notes sustained demand for MannKind's capabilities, justifying the Buy rating. H.C. Wainwright also supports this with a Buy rating and an $8 price target."
datetime: "2026-05-06T18:15:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285419979.md)
  - [en](https://longbridge.com/en/news/285419979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285419979.md)
---

# MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged

Wedbush analyst Yun Zhong has maintained their bullish stance on MNKD stock, giving a Buy rating on April 23.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Yun Zhong has given his Buy rating due to a combination of factors tied to MannKind’s expanding role in United Therapeutics’ inhaled portfolio and the long-term potential of the ralinepag DPI program. The decision by United Therapeutics to exercise its exclusive option for a second DPI product, backed by favorable pharmacokinetic and digital lung modeling data, underscores confidence in MannKind’s inhalation technology and intellectual property.

Yun also highlights that United Therapeutics’ bullish positioning of ralinepag as a major future franchise, along with planned indications beyond pulmonary arterial hypertension, supports a robust, multi-year revenue opportunity for MannKind through manufacturing and royalty streams. In addition, current Tyvaso DPI sales and the planned bridging study for IPF reinforce sustained demand for MannKind’s capacity and capabilities, justifying a continued Buy rating with an unchanged $8 price target.

In another report released on April 23, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.

### Related Stocks

- [MNKD.US](https://longbridge.com/en/quote/MNKD.US.md)
- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 | UTHR Stock News](https://longbridge.com/en/news/286679932.md)
- [TD Cowen Reaffirms Their Buy Rating on United Therapeutics (UTHR)](https://longbridge.com/en/news/286711472.md)
- [Ameritas Advisory Services LLC Boosts Stake in United Therapeutics Corporation $UTHR](https://longbridge.com/en/news/286373098.md)
- [United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares](https://longbridge.com/en/news/286643771.md)
- [Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease | UTHR Stock News](https://longbridge.com/en/news/286236984.md)